Clinical Outcomes and Molecular Profiling of Pancreatic Acinar Cell Carcinoma: A Retrospective Study
JCO Precision Oncology · 2025
DOI: 10.1200/po-24-00450 ↗Kurz gefasst
Fachartikel in der Zeitschrift JCO Precision Oncology, 2025. Verfasst von Cody Eslinger und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology and Oncology, Mayo Clinic, Phoenix, AZ. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, Carcinoma, Acinar Cell. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
PURPOSE Pancreatic acinar cell carcinoma (PACC) is a rare and aggressive form of pancreatic cancer that originates in the acinar cells of the exocrine pancreas. In this study, we aimed to investigate the clinical and molecular characteristics of patients with PACC at our institution. METHODS This was a retrospective study of patients with PACC seen at Mayo Clinic between 2002 and 2023. Baseline patient characteristics, tumor pathology, treatment strategies used, and survival outcomes were analyzed. Kaplan-Meier curves were estimated using newsurv macros in SAS. RESULTS The study included a total of 65 patients with PACC. The median age at diagnosis was 66 years. Almost half of the patients (48%) presented with resectable/borderline-resectable disease (n = 28). Five-year overall survival (OS) for resectable/borderline-resectable, locally advanced/unresectable, and metastatic disease were 72.0%, 21.6%, and 20.9%, respectively. Somatic and germline next-generation sequencing identified numerous potentially actionable targets including homologous recombination (43% somatic, 33% germline), RAF alterations (29% somatic), and mismatch repair (14% somatic). CONCLUSION Our findings underscore the heterogeneity and aggressive nature of PACC. Despite the improved prognosis for patients with resectable/borderline-resectable disease, OS remains poor, particularly for those with locally advanced or metastatic disease. The identification of actionable molecular targets in a significant proportion of patients highlights the potential for personalized therapeutic approaches. Future research should focus on tailored treatment strategies to exploit these molecular vulnerabilities, which may offer new options for improving outcomes in this rare malignancy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Department of Hematology and Oncology, Mayo Clinic, Phoenix, AZ.
- Department of Clinical Trials and Biostatistics, Mayo Clinic, Phoenix, AZ.
- Department of Laboratory Medicine and Pathology, Mayo Clinic, Phoenix, AZ.
- Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN.
- Department of Hematology and Oncology, Mayo Clinic, Jacksonville, FL.
- Department of Medical Oncology, Mayo Clinic, Rochester, MN.
ORCID-Profile: Cody Eslinger, Claire Yee, Zaid Elsabbagh, Chris Hartley, Jason Starr, Tanios Bekaii-Saab, Thorvardur R Halfdanarson, Mohamad Bassam Sonbol
Zitieren
APA
Eslinger, C., Seddighzadeh, B., Yee, C., Elsabbagh, Z., Pai, R., Hartley, C., Starr, J., Bekaii-Saab, T., Halfdanarson, T. R., & Sonbol, M. B. (2025). Clinical Outcomes and Molecular Profiling of Pancreatic Acinar Cell Carcinoma: A Retrospective Study. JCO Precision Oncology. https://doi.org/10.1200/po-24-00450
Vancouver
Eslinger C, Seddighzadeh B, Yee C, Elsabbagh Z, Pai R, Hartley C, et al. Clinical Outcomes and Molecular Profiling of Pancreatic Acinar Cell Carcinoma: A Retrospective Study. JCO Precision Oncology. 2025. doi:10.1200/po-24-00450
BibTeX
@article{Eslinger2025,
author = {Eslinger, Cody and Seddighzadeh, Bobak and Yee, Claire and Elsabbagh, Zaid and Pai, Rish and Hartley, Chris and Starr, Jason and Bekaii-Saab, Tanios and Halfdanarson, Thorvardur R and Sonbol, Mohamad Bassam},
title = {Clinical Outcomes and Molecular Profiling of Pancreatic Acinar Cell Carcinoma: A Retrospective Study},
journal = {JCO Precision Oncology},
year = {2025},
doi = {10.1200/po-24-00450}
}
EUVIMED